1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Bipartisan Support For AdvaMed’s Legislative Priorities, Whitaker Says

 
• By Brian Bossetta

AdvaMed’s Scott Whitaker and Michael Minogue outlined the trade group’s legislative goals for the rest of the year, chief among them regulatory oversight for lab-developed tests.

legislation
• Source: Shutterstock

Ahead of the 2022 MedTech Conference in Boston, which will be held in person for the first time since before the COVID-19 pandemic, AdvaMed CEO Scott Whitaker and AdvaMed Chair and Abiomed CEO Michael Minogue offered a preview of the trade group’s legislative priorities during a press conference.

AdvaMed’s focus, Whitaker said, is threefold: FDA oversight of lab-developed tests (LDTs), FDA certificates to foreign governments (CFGs), and FDA authority concerning artificial intelligence (AI) and machine learning (ML) devices....

More from Regulation

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 
• By Brian Bossetta

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 
• By Amanda Maxwell

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.